Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
21 |
Material Type: Web Resources
|
Benzinga: Bristol Myers Unveils More Mavacamten Data To Backup Case For Heart DrugNewstex Finance & Accounting Blogs, 2021Copyright Newstex May 17, 2021Digital Resources/Online E-Resources |
|
22 |
Material Type: Web Resources
|
Benzinga: Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: AnalystNewstex Finance & Accounting Blogs, 2024Copyright Newstex Jan 12, 2024Digital Resources/Online E-Resources |
|
23 |
Material Type: Web Resources
|
NJ Spotlight - WNET Spotlight LLC: Pallones fight against sudden cardiac arrest in kidsNJ Spotlight News, 2023Copyright Newstex Dec 19, 2023Digital Resources/Online E-Resources |
|
24 |
Material Type: Web Resources
|
24/7 Wall St.: Could Applied Therapeutics Stock Rise 300%?Newstex Finance & Accounting Blogs, 2020Copyright Newstex Oct 8, 2020Digital Resources/Online E-Resources |
|
25 |
Material Type: Web Resources
|
PharmaTimes: First treatment for ‘broken heart syndrome’ trialledPharmaTimes, 2022Copyright Newstex Jun 29, 2022Digital Resources/Online E-Resources |
|
26 |
Material Type: Web Resources
|
Benzinga: Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA ApprovalNewstex Finance & Accounting Blogs, 2022Copyright Newstex Oct 3, 2022Digital Resources/Online E-Resources |
|
27 |
Material Type: Web Resources
|
Benzinga: Sangamo's Fabry Disease Gene Therapy Continues To Show Encouraging Safety ProfileNewstex Finance & Accounting Blogs, 2022Copyright Newstex Aug 30, 2022Digital Resources/Online E-Resources |
|
28 |
Material Type: Web Resources
|
Trefis: Is Alnylam Stock Poised For More Gains After A Stellar 50% Rise In A Month?Newstex Finance & Accounting Blogs, 2022Copyright Newstex Aug 22, 2022Digital Resources/Online E-Resources |
|
29 |
Material Type: Web Resources
|
PharmaTimes: NICE rejects Pfizer’s rare heart disease treatment VyndaqelPharmaTimes, 2021Copyright Newstex May 12, 2021Digital Resources/Online E-Resources |
|
30 |
Material Type: Web Resources
|
Newsfile Corp.: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYNewstex Finance & Accounting Blogs, 2023Copyright Newstex Nov 30, 2023Digital Resources/Online E-Resources |
|
31 |
Material Type: Web Resources
|
GuruFocus.com: Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating ThroughNewstex Finance & Accounting Blogs, 2024Copyright Newstex May 9, 2024Digital Resources/Online E-Resources |
|
32 |
Material Type: Web Resources
|
Newsfile Corp.: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYNewstex Finance & Accounting Blogs, 2023Copyright Newstex Nov 17, 2023Digital Resources/Online E-Resources |
|
33 |
Material Type: Web Resources
|
Newsfile Corp.: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYNewstex Finance & Accounting Blogs, 2023Copyright Newstex Nov 9, 2023Digital Resources/Online E-Resources |
|
34 |
Material Type: Web Resources
|
Newsfile Corp.: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYNewstex Finance & Accounting Blogs, 2023Copyright Newstex Nov 1, 2023Digital Resources/Online E-Resources |
|
35 |
Material Type: Web Resources
|
Newsfile Corp.: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYNewstex Finance & Accounting Blogs, 2023Copyright Newstex Oct 23, 2023Digital Resources/Online E-Resources |
|
36 |
Material Type: Web Resources
|
Watchlist News - American Consumer News: Hemostemix Inc. (HEM.V) (CVE:HEM) Stock Price Passes Below Fifty Day Moving Average of $0.49Newstex Finance & Accounting Blogs, 2021Copyright Newstex Feb 27, 2021Digital Resources/Online E-Resources |
|
37 |
Material Type: Web Resources
|
American Banking and Market News - American Consumer News: Hemostemix Inc. (HEM.V) (CVE:HEM) Stock Price Passes Below Fifty Day Moving Average of $0.49Newstex Finance & Accounting Blogs, 2021Copyright Newstex Feb 27, 2021Digital Resources/Online E-Resources |
|
38 |
Material Type: Web Resources
|
Newsfile Corp.: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYNewstex Finance & Accounting Blogs, 2023Copyright Newstex Oct 15, 2023Digital Resources/Online E-Resources |
|
39 |
Material Type: Web Resources
|
American Banking and Market News - American Consumer News: Hemostemix Inc. (HEM.V) (CVE:HEM) Stock Price Passes Below 50 Day Moving Average of $0.46Newstex Finance & Accounting Blogs, 2021Copyright Newstex Feb 11, 2021Digital Resources/Online E-Resources |
|
40 |
Material Type: Web Resources
|
American Banking and Market News - American Consumer News: Hemostemix Inc. (HEM.V) (CVE:HEM) Shares Gap Down to $0.59Newstex Finance & Accounting Blogs, 2021Copyright Newstex Feb 1, 2021Digital Resources/Online E-Resources |